Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Bissonnette

Showing results (61-70 of 222) with videos related to

Pageof 23
Sort By:
International Journal of Dermatology|July 13, 2010
Safety profile of intravenous and subcutaneous siplizumab, an anti-CD2 monoclonal antibody, for the treatment of plaque psoriasis: results of two randomized, double-blind, placebo-controlled studiesRichard G Langley, Kim Papp, Robert Bissonnette, et al.
Journal of Cutaneous Medicine and Surgery|November 16, 2018
Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. Section II: Tools for Assessing the Severity of Atopic DermatitisMelinda J Gooderham, Robert Bissonnette, Parbeer Grewal, et al.
Journal of Drugs in Dermatology : JDD|August 13, 2015
Randomized Pilot Clinical Trial of Tofacitinib Solution for Plaque Psoriasis: Challenges of the Intra-Subject Study DesignWilliam C Ports, Steven R Feldman, Pankaj Gupta, et al.
American Journal of Clinical Dermatology|March 18, 2018
Prevention and Reduction of Atrophic Acne Scars with Adapalene 0.3%/Benzoyl Peroxide 2.5% Gel in Subjects with Moderate or Severe Facial Acne: Results of a 6-Month Randomized, Vehicle-Controlled Trial Using Intra-Individual ComparisonBrigitte Dréno, Robert Bissonnette, Angélique Gagné-Henley, et al.
American Journal of Clinical Dermatology|April 4, 2022
A Maximum-Use Trial of Ruxolitinib Cream in Adolescents and Adults with Atopic DermatitisRobert Bissonnette, Robert S Call, Tooraj Raoof, et al.
Clinical Pharmacology in Drug Development|February 2, 2018
Systemic Pharmacokinetics, Safety, and Preliminary Efficacy of Topical AhR Agonist Tapinarof: Results of a Phase 1 StudyRobert Bissonnette, Lakshmi S Vasist, Jonathan N Bullman, et al.
Journal of Cutaneous Medicine and Surgery|July 26, 2011
Support needed to involve psoriasis patients in treatment decisions: survey of dermatologistsJerry Tan, Dawn Stacey, Benjamin Barankin, et al.
Journal of the American Academy of Dermatology|January 8, 2019
Phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of plaque psoriasisKevin Robbins, Robert Bissonnette, Tomoko Maeda-Chubachi, et al.
Archives of Dermatology|April 21, 2010
Efficacy and safety of topical WBI-1001 in the treatment of atopic dermatitis: results from a phase 2A, randomized, placebo-controlled clinical trialRobert Bissonnette, Genhui Chen, Chantal Bolduc, et al.
Dermatology and Therapy|October 30, 2021
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar PustulosisRobert Bissonnette, Catherine Maari, Athanasios Tsianakas, et al.
Pageof 23

Showing results (61-70 of 222) with videos related to

Sort By:
Pageof 23
International Journal of Dermatology|July 13, 2010
Safety profile of intravenous and subcutaneous siplizumab, an anti-CD2 monoclonal antibody, for the treatment of plaque psoriasis: results of two randomized, double-blind, placebo-controlled studiesRichard G Langley, Kim Papp, Robert Bissonnette, et al.
Journal of Cutaneous Medicine and Surgery|November 16, 2018
Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. Section II: Tools for Assessing the Severity of Atopic DermatitisMelinda J Gooderham, Robert Bissonnette, Parbeer Grewal, et al.
Journal of Drugs in Dermatology : JDD|August 13, 2015
Randomized Pilot Clinical Trial of Tofacitinib Solution for Plaque Psoriasis: Challenges of the Intra-Subject Study DesignWilliam C Ports, Steven R Feldman, Pankaj Gupta, et al.
American Journal of Clinical Dermatology|March 18, 2018
Prevention and Reduction of Atrophic Acne Scars with Adapalene 0.3%/Benzoyl Peroxide 2.5% Gel in Subjects with Moderate or Severe Facial Acne: Results of a 6-Month Randomized, Vehicle-Controlled Trial Using Intra-Individual ComparisonBrigitte Dréno, Robert Bissonnette, Angélique Gagné-Henley, et al.
American Journal of Clinical Dermatology|April 4, 2022
A Maximum-Use Trial of Ruxolitinib Cream in Adolescents and Adults with Atopic DermatitisRobert Bissonnette, Robert S Call, Tooraj Raoof, et al.
Clinical Pharmacology in Drug Development|February 2, 2018
Systemic Pharmacokinetics, Safety, and Preliminary Efficacy of Topical AhR Agonist Tapinarof: Results of a Phase 1 StudyRobert Bissonnette, Lakshmi S Vasist, Jonathan N Bullman, et al.
Journal of Cutaneous Medicine and Surgery|July 26, 2011
Support needed to involve psoriasis patients in treatment decisions: survey of dermatologistsJerry Tan, Dawn Stacey, Benjamin Barankin, et al.
Journal of the American Academy of Dermatology|January 8, 2019
Phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of plaque psoriasisKevin Robbins, Robert Bissonnette, Tomoko Maeda-Chubachi, et al.
Archives of Dermatology|April 21, 2010
Efficacy and safety of topical WBI-1001 in the treatment of atopic dermatitis: results from a phase 2A, randomized, placebo-controlled clinical trialRobert Bissonnette, Genhui Chen, Chantal Bolduc, et al.
Dermatology and Therapy|October 30, 2021
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar PustulosisRobert Bissonnette, Catherine Maari, Athanasios Tsianakas, et al.
Pageof 23